Daiichi SankyoDaiichi Sankyo, the global pharmaceutical company with corporate origins in Japan is seeking research collaborations with UK entities in a number of key areas. The Department for International Trade worked with Daiichi Sankyo and One Nucleus to organise a free webinar to enable you to learn about the Daiichi Sankyo research priorities and collaboration structures available. The core areas of interest include:
- Novel modality technologies in oncology and CNS (psychiatric and neurodegenerative disease)
- Ex) Target protein degrader (except E3 binder), conditional active antibody (except pH-dependent), next generation of gene therapy etc
- Novel drug delivery technologies to cancer cells or brain after systemic administration
- Ex) Engineered nanoparticle/exosome etc Novel target or cancer-specific antigen for antibody in oncology
This content has been restricted to logged in users only. Please login to view this content.